{"id":3764,"date":"2022-08-02T09:30:47","date_gmt":"2022-08-02T01:30:47","guid":{"rendered":"https:\/\/regask.com\/?p=3764"},"modified":"2024-10-25T00:45:40","modified_gmt":"2024-10-24T16:45:40","slug":"priorites-de-conformite-de-laustralie-2022","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/australia-compliance-priorities-2022\/","title":{"rendered":"Australie : normes de conformit\u00e9 en mati\u00e8re d'importation, de publicit\u00e9 et d'approvisionne\u2026"},"content":{"rendered":"

Le TGA<\/a> a publi\u00e9 une liste de priorit\u00e9s en mati\u00e8re de conformit\u00e9 en mati\u00e8re d'importation, de publicit\u00e9 et d'approvisionnement du 1er juillet 2022 au 30 juin 2023 :<\/p>\n

    \n
  1. D\u00e9courager et lutter contre l\u2019importation, la publicit\u00e9 et la fourniture ill\u00e9gales de produits th\u00e9rapeutiques non approuv\u00e9s associ\u00e9s \u00e0 la COVID-19.<\/strong><\/li>\n
  2. Perturber et lutter contre l\u2019importation, la publicit\u00e9 et la fourniture ill\u00e9gales de produits de vapotage \u00e0 la nicotine.<\/strong><\/li>\n
  3. Assurer le respect des exigences de la loi sur les produits th\u00e9rapeutiques de 1989 dans l'ensemble du pays.\u00a0industrie du cannabis m\u00e9dicinal<\/strong><\/li>\n
  4. Perturber et lutter contre l\u2019importation, la fabrication, la publicit\u00e9 et la fourniture ill\u00e9gales de produits th\u00e9rapeutiques non approuv\u00e9s am\u00e9liorant les performances et l'image, y compris les compl\u00e9ments sportifs, <\/strong>en mettant l\u2019accent sur les produits contenant des poisons des tableaux 4 et 8.<\/li>\n
  5. D\u00e9courager et lutter contre l\u2019importation, la publicit\u00e9 et la fourniture ill\u00e9gales de produits th\u00e9rapeutiques non approuv\u00e9s utilis\u00e9s dans l\u2019industrie de la beaut\u00e9 et de la dentisterie cosm\u00e9tique.<\/strong><\/li>\n
  6. Adressez-vous \u00e0 la\u00a0utilisation illicite de repr\u00e9sentations restreintes et interdites\u00a0<\/strong>dans les publicit\u00e9s qui n\u2019ont pas \u00e9t\u00e9 approuv\u00e9es ou autoris\u00e9es, en particulier celles qui ciblent les consommateurs particuli\u00e8rement vuln\u00e9rables<\/li>\n
  7. Dissuader et lutter contre la publicit\u00e9 ill\u00e9gale\u00a0produits th\u00e9rapeutiques non homologu\u00e9s sur les plateformes de commerce \u00e9lectronique ;\u00a0<\/strong>y compris pour les produits de grossesse et pr\u00e9natals, les produits de perte de poids et les rem\u00e8des contre la gueule de bois.<\/li>\n<\/ol>\n
    \n
    \n
    \n
    \n

    En ce qui concerne le point 4, la TGA propose de se concentrer sur l'importation, la fabrication, la publicit\u00e9, la composition et la fourniture de produits non approuv\u00e9s. Cette mesure s'accompagnera d'une \u00e9ducation des consommateurs et d'un ciblage des plateformes en ligne faisant la publicit\u00e9 de compl\u00e9ments sportifs non approuv\u00e9s.<\/p>\n

    En ce qui concerne le point 6, la TGA se concentrera sur les publicit\u00e9s ill\u00e9gales li\u00e9es \u00e0 des maladies ou affections graves pour lesquelles le sponsor ne d\u00e9tient pas de preuves appropri\u00e9es pour l'indication et n'a pas inscrit l'indication sur le site Web.\u00a0Australie<\/span>n Registre des produits th\u00e9rapeutiques.<\/p>\n

    En ce qui concerne le point 7, la TGA a identifi\u00e9 des m\u00e9dicaments compl\u00e9mentaires non approuv\u00e9s annonc\u00e9s et vendus via des plateformes en ligne et ceux qui incluent des t\u00e9moignages ill\u00e9gaux et des indications non fond\u00e9es. Les activit\u00e9s de conformit\u00e9 comprendront la surveillance des produits th\u00e9rapeutiques non approuv\u00e9s, des produits th\u00e9rapeutiques approuv\u00e9s avec des indications et des all\u00e9gations non approuv\u00e9es et des t\u00e9moignages ill\u00e9gaux qui ne sont pas conformes au code de publicit\u00e9 des produits th\u00e9rapeutiques. Les domaines d'int\u00e9r\u00eat sont la grossesse, les soins pr\u00e9natals, la perte de poids et les rem\u00e8des contre la gueule de bois.<\/p>\n

    D'autres domaines prioritaires de conformit\u00e9 pourraient appara\u00eetre au cours de l'ann\u00e9e et \u00eatre ajout\u00e9s \u00e0 la liste. Ces priorit\u00e9s s'ajoutent aux programmes de conformit\u00e9 r\u00e9guliers de la TGA pour les listes de m\u00e9decines compl\u00e9mentaires (examens post-commercialisation), la surveillance et la vigilance des inclusions de dispositifs m\u00e9dicaux, les programmes de pharmacovigilance et d'inspection des bonnes pratiques cliniques, ainsi que le programme de conformit\u00e9 aux BPF.<\/p>\n

    \n
    \n
    \n
    \n
    \n
    \n
    \n
    \n
    \n
    \n
    \n

    Contactez RegASK pour en savoir plus sur les changements r\u00e9glementaires en Australie.\u00a0<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\t\tContactez RegASK pour plus de d\u00e9tails<\/span>\n\t<\/a>\n\n\n\t\tEn savoir plus<\/span>\n\t<\/a>\n\n

    \n\n\t
    \n\t\t\t\t
    \n\t\t\t\n\t\t\t\n\n\t\tLisez les \u00e9tudes de cas sur l'industrie pharmaceutique et biotechnologique<\/span>\n\t<\/a>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n<\/div>\n
    \n
    \n
    <\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

    La TGA a publi\u00e9 une liste de priorit\u00e9s en mati\u00e8re de conformit\u00e9 en mati\u00e8re d'importation, de publicit\u00e9 et d'approvisionnement du 1er juillet 2022 au 30 juin 2023 : D\u00e9courager et lutter contre l'importation, la publicit\u00e9 et la fourniture ill\u00e9gales de produits th\u00e9rapeutiques non approuv\u00e9s associ\u00e9s \u00e0 la COVID-19. Interrompre et lutter contre l'importation, la publicit\u00e9 et la fourniture ill\u00e9gales de produits de vapotage \u00e0 la nicotine. Assurer le respect des exigences\u2026<\/p>","protected":false},"author":39,"featured_media":2487,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[511,35],"tags":[40],"class_list":["post-3764","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-australia-regulations","category-pharma-biotech-latest-insights","tag-latest-insights"],"acf":[],"yoast_head":"\nAustralia: Import, Ads & Supply Compliance Priorities 2022 | RegASK<\/title>\n<meta name=\"description\" content=\"Australia's TGA has published a list of import, advertising and supply compliance priorities from I July 2022 to 30 June 2023.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/priorites-de-conformite-de-laustralie-2022\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Australia: Import, Advertising and Supply Compliance Priorities 2022-23\" \/>\n<meta property=\"og:description\" content=\"Australia's TGA has published a list of import, advertising and supply compliance priorities from I July 2022 to 30 June 2023.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/priorites-de-conformite-de-laustralie-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-02T01:30:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-24T16:45:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2021\/04\/pharma-pills.png\" \/>\n\t<meta property=\"og:image:width\" content=\"689\" \/>\n\t<meta property=\"og:image:height\" content=\"626\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Benoit Trouwaert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benoit Trouwaert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/australia-compliance-priorities-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/australia-compliance-priorities-2022\\\/\"},\"author\":{\"name\":\"Benoit Trouwaert\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/c1d261e8dcf7b1c30b2c4f2c119df42d\"},\"headline\":\"Australia: Import, Advertising and Supply Compliance Pr…\",\"datePublished\":\"2022-08-02T01:30:47+00:00\",\"dateModified\":\"2024-10-24T16:45:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/australia-compliance-priorities-2022\\\/\"},\"wordCount\":444,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/australia-compliance-priorities-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/pharma-pills.png\",\"keywords\":[\"Latest Insights\"],\"articleSection\":[\"Australia\",\"Pharma and Biotech\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/australia-compliance-priorities-2022\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/australia-compliance-priorities-2022\\\/\",\"name\":\"Australia: Import, Ads & Supply Compliance Priorities 2022 | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/australia-compliance-priorities-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/australia-compliance-priorities-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/pharma-pills.png\",\"datePublished\":\"2022-08-02T01:30:47+00:00\",\"dateModified\":\"2024-10-24T16:45:40+00:00\",\"description\":\"Australia's TGA has published a list of import, advertising and supply compliance priorities from I July 2022 to 30 June 2023.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/australia-compliance-priorities-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/australia-compliance-priorities-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/pharma-pills.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/pharma-pills.png\",\"width\":689,\"height\":626,\"caption\":\"Medication tablets\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"Empowering Smarter Regulatory Decisions\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/c1d261e8dcf7b1c30b2c4f2c119df42d\",\"name\":\"Benoit Trouwaert\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Australie : priorit\u00e9s en mati\u00e8re de conformit\u00e9 des importations, des publicit\u00e9s et de l'approvisionnement en 2022 | RegASK","description":"La TGA australienne a publi\u00e9 une liste de priorit\u00e9s en mati\u00e8re de conformit\u00e9 en mati\u00e8re d'importation, de publicit\u00e9 et d'approvisionnement du 1er juillet 2022 au 30 juin 2023.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/priorites-de-conformite-de-laustralie-2022\/","og_locale":"fr_FR","og_type":"article","og_title":"Australia: Import, Advertising and Supply Compliance Priorities 2022-23","og_description":"Australia's TGA has published a list of import, advertising and supply compliance priorities from I July 2022 to 30 June 2023.","og_url":"https:\/\/regask.com\/fr\/priorites-de-conformite-de-laustralie-2022\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2022-08-02T01:30:47+00:00","article_modified_time":"2024-10-24T16:45:40+00:00","og_image":[{"width":689,"height":626,"url":"https:\/\/regask.com\/wp-content\/uploads\/2021\/04\/pharma-pills.png","type":"image\/png"}],"author":"Benoit Trouwaert","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Benoit Trouwaert","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/australia-compliance-priorities-2022\/#article","isPartOf":{"@id":"https:\/\/regask.com\/australia-compliance-priorities-2022\/"},"author":{"name":"Benoit Trouwaert","@id":"https:\/\/regask.com\/#\/schema\/person\/c1d261e8dcf7b1c30b2c4f2c119df42d"},"headline":"Australia: Import, Advertising and Supply Compliance Pr…","datePublished":"2022-08-02T01:30:47+00:00","dateModified":"2024-10-24T16:45:40+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/australia-compliance-priorities-2022\/"},"wordCount":444,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/australia-compliance-priorities-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2021\/04\/pharma-pills.png","keywords":["Latest Insights"],"articleSection":["Australia","Pharma and Biotech"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/australia-compliance-priorities-2022\/","url":"https:\/\/regask.com\/australia-compliance-priorities-2022\/","name":"Australie : priorit\u00e9s en mati\u00e8re de conformit\u00e9 des importations, des publicit\u00e9s et de l'approvisionnement en 2022 | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/australia-compliance-priorities-2022\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/australia-compliance-priorities-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2021\/04\/pharma-pills.png","datePublished":"2022-08-02T01:30:47+00:00","dateModified":"2024-10-24T16:45:40+00:00","description":"La TGA australienne a publi\u00e9 une liste de priorit\u00e9s en mati\u00e8re de conformit\u00e9 en mati\u00e8re d'importation, de publicit\u00e9 et d'approvisionnement du 1er juillet 2022 au 30 juin 2023.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/australia-compliance-priorities-2022\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/australia-compliance-priorities-2022\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2021\/04\/pharma-pills.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2021\/04\/pharma-pills.png","width":689,"height":626,"caption":"Medication tablets"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Favoriser des d\u00e9cisions r\u00e9glementaires plus intelligentes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd"]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/c1d261e8dcf7b1c30b2c4f2c119df42d","name":"Beno\u00eet Trouwaert"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/3764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/39"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=3764"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/3764\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/2487"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=3764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=3764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=3764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}